Table 3.
Dose reduction and treatment stop.
| n, % | n = 11 | Definitive Discontinuation of Treatments (n = 8) | |||
|---|---|---|---|---|---|
| Dose Reduction for Toxicities | Treatment Stop due to Toxicities | Treatment Stop due to Progression | Treatment Stop Planned by the Protocol | Treatment Stop for Other Reason(s) * | |
| Irinotecan (n = 11) | 2 (18.2%) | 1 (12.5%) | 6 (75.0%) | 0 | 1 (12.5%) |
| 5FU bolus (n = 11) | 2 (18.2%) | 0 | 7 (87.5%) | 0 | 1 (12.5%) |
| Continuous 5FU (n = 11) | 3 (27.3%) | 0 | 7 (87.5%) | 0 | 1 (12.5%) |
| Durvalumab (n = 11) | 0 | 0 | 7 (87.5%) | 0 | 1 (12.5%) |
| Tremelimumab (n = 3) | 0 | 0 | 2 (66.7%) | 1 (33.3%) | 0 |
* Infectious pneumonia not related to the treatment.